Chief Financial Officer · Trevi Therapeutics, Inc. (TRVI)

Lisa Delfini

FY2024 is the first fiscal year CompBrief holds for Lisa Delfini as a named executive officer of Trevi Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,187,403

Salary $412,169Stock awards $0Bonus $182,160

3rd of 3 named executive officers at Trevi Therapeutics by FY2024 total.

3 named officers on file for Trevi Therapeutics, FY2024

Lisa Delfini’s pay file — $29

  • 1 fiscal year of pay, line by line
  • TRVI’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Trevi Therapeutics’s whole pay program stands against its peers

  • Trevi Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TRVI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Lisa Delfini’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Lisa Delfini compensation by year

Trevi Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Trevi Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$412,169
Bonus$182,160
Stock awards$0
Option awards$582,724
Non-equity incentive$0
Pension and deferred compensation$0
All other$10,350
Total$1,187,403

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Trevi Therapeutics, Inc. DEF 14A filed April 29, 2025, accession 0000950170-25-059628, and prior-year filings.

How this page was built: the Trevi Therapeutics, Inc. filed document, accession 0000950170-25-059628. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option16,667—$1.97
Option32,084—$0.51
Option101,563—$2.67
Option175,000—$2.38
Option120,000—$2.38

Per the Outstanding Equity Awards at Fiscal Year-End table in Trevi Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2024 proxy (filed April 29, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-05-31Grant or award derivative—72,000$0.00110,400

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Trevi Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Jennifer GoodPresident and Chief Executive Officer$2,589,035
James CassellaChief Development Officer$1,441,119
Lisa Delfini · this pageChief Financial Officer$1,187,403

The full Trevi Therapeutics compensation record

free company brief

This page is one person within Trevi Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Trevi Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Trevi Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Lisa Delfini's compensation dossier · One-time report. No refunds.